Trial Profile
Babies Born Early Antibody Response to Men B Vaccination: A Phase IV Multicentre Randomised Study to Evaluate the Primary and Booster Immune Responses in UK Preterm Infants Receiving Routine Immunisations and Incorporating a Three Dose Versus a Two Dose Schedule of 4CMenB (Bexsero) for Primary Immunisation.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Meningococcal vaccine group B OMV Novartis (Primary)
- Indications Meningococcal group B infections
- Focus Pharmacodynamics
- Acronyms BEAR Men B
- 28 Jul 2020 Planned End Date changed from 2 Jan 2020 to 30 Sep 2020.
- 29 Jan 2019 Planned End Date changed from 2 Aug 2019 to 2 Jan 2020.
- 29 Jan 2019 Planned primary completion date changed from 2 Jan 2019 to 2 Sep 2019.